Scholar Rock Holding (SRRK) Change in Receivables (2020)
Scholar Rock Holding (SRRK) posted quarterly Change in Receivables of -$25.0 million for Q1 2020.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Change in Receivables (2020) Analysis & Trends
Scholar Rock Holding's Change in Receivables history runs 1 years deep, the most recent figure standing at -$25.0 million for Q1 2020.
- In Q1 2020, Change in Receivables changed N/A year-over-year to -$25.0 million; the TTM figure through Dec 2020 stood at -$25.0 million (changed N/A YoY), while the FY2020 annual figure was -$25.0 million, down 200.0% from the prior year.
- Change in Receivables for Q1 2020 stood at -$25.0 million.
- The five-year high for Change in Receivables was -$25.0 million in Q1 2020, with the low at -$25.0 million in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Scholar Rock Holding | 7.25 Bn | 7.25 Bn | - | - |